<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Argenx Se — News on 6ix</title>
<link>https://6ix.com/company/argenx-se</link>
<description>Latest news and press releases for Argenx Se on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 20 Mar 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/argenx-se" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68cd1beedb30cb6fef02b.webp</url>
<title>Argenx Se</title>
<link>https://6ix.com/company/argenx-se</link>
</image>
<item>
<title>argenx announces Annual General Meeting of Shareholders on May 6, 2026</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026-1</guid>
<pubDate>Fri, 20 Mar 2026 20:01:00 GMT</pubDate>
<description>March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual Gen</description>
</item>
<item>
<title>Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics</title>
<link>https://6ix.com/company/argenx-se/news/unnatural-products-raises-dollar45-million-series-b-financing-to-advance-macrocyclic-peptide-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/unnatural-products-raises-dollar45-million-series-b-financing-to-advance-macrocyclic-peptide-therapeutics</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investorsSANTA CRUZ, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia</description>
</item>
<item>
<title>argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-10</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-10</guid>
<pubDate>Fri, 06 Mar 2026 06:00:00 GMT</pubDate>
<description>Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART’s efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART’s expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (</description>
</item>
<item>
<title>argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
<link>https://6ix.com/company/argenx-se/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</guid>
<pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
<description>$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Am</description>
</item>
<item>
<title>argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis-1</guid>
<pubDate>Thu, 26 Feb 2026 05:30:00 GMT</pubDate>
<description>Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the</description>
</item>
<item>
<title>argenx to Present at TD Cowen 46th Annual Healthcare Conference</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference-1</guid>
<pubDate>Mon, 23 Feb 2026 06:00:00 GMT</pubDate>
<description>February 23, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors.</description>
</item>
<item>
<title>argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026-1</guid>
<pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
<description>February 19, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx w</description>
</item>
<item>
<title>argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-in-achr-ab-seronegative-gmg</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-in-achr-ab-seronegative-gmg</guid>
<pubDate>Tue, 13 Jan 2026 06:00:00 GMT</pubDate>
<description>January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalize</description>
</item>
<item>
<title>argenx Highlights 2026 Strategic Priorities</title>
<link>https://6ix.com/company/argenx-se/news/argenx-highlights-2026-strategic-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-highlights-2026-strategic-priorities</guid>
<pubDate>Mon, 12 Jan 2026 06:00:00 GMT</pubDate>
<description>Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; thre</description>
</item>
<item>
<title>argenx to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 06:00:00 GMT</pubDate>
<description>January 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl</description>
</item>
<item>
<title>argenx Announces Leadership Transition Marking Next Evolution of Growth</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-leadership-transition-marking-next-evolution-of-growth</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-leadership-transition-marking-next-evolution-of-growth</guid>
<pubDate>Mon, 05 Jan 2026 06:00:00 GMT</pubDate>
<description>Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and</description>
</item>
<item>
<title>argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease</title>
<link>https://6ix.com/company/argenx-se/news/argenx-provides-update-on-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-provides-update-on-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease</guid>
<pubDate>Mon, 15 Dec 2025 06:00:00 GMT</pubDate>
<description>15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Mo</description>
</item>
<item>
<title>argenx Announces Results of Extraordinary General Meeting of Shareholders</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders</guid>
<pubDate>Tue, 18 Nov 2025 21:01:00 GMT</pubDate>
<description>November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025. The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majorit</description>
</item>
<item>
<title>/C O R R E C T I O N from source -- argenx Canada Inc./</title>
<link>https://6ix.com/company/argenx-se/news/c-o-r-r-e-c-t-i-o-n-from-source-argenx-canada-inc</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/c-o-r-r-e-c-t-i-o-n-from-source-argenx-canada-inc</guid>
<pubDate>Wed, 05 Nov 2025 20:30:00 GMT</pubDate>
<description>argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC (efgartigimod alfa injection) as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP).</description>
</item>
<item>
<title>argenx Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/argenx-se/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-1</guid>
<pubDate>Thu, 30 Oct 2025 06:00:00 GMT</pubDate>
<description>$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to imp</description>
</item>
<item>
<title>argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients</title>
<link>https://6ix.com/company/argenx-se/news/argenx-presents-new-data-at-aanem-and-mgfa-highlighting-the-strength-and-broad-benefit-of-vyvgart-for-myasthenia-gravis-patients</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-presents-new-data-at-aanem-and-mgfa-highlighting-the-strength-and-broad-benefit-of-vyvgart-for-myasthenia-gravis-patients</guid>
<pubDate>Wed, 29 Oct 2025 15:00:00 GMT</pubDate>
<description>VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE for at least 4 weeks Real world data show >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit October 29, 2025, 8:00 AM PT Amsterdam, the Neth</description>
</item>
<item>
<title>argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-report-third-quarter-2025-financial-results-and-business-update-on-october-30-2025</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-report-third-quarter-2025-financial-results-and-business-update-on-october-30-2025</guid>
<pubDate>Thu, 23 Oct 2025 05:00:00 GMT</pubDate>
<description>October 23, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at arg</description>
</item>
<item>
<title>argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session</title>
<link>https://6ix.com/company/argenx-se/news/argenx-to-highlight-key-data-and-breadth-of-immunology-innovation-at-2025-aanem-annual-meeting-and-mgfa-scientific-session</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-to-highlight-key-data-and-breadth-of-immunology-innovation-at-2025-aanem-annual-meeting-and-mgfa-scientific-session</guid>
<pubDate>Wed, 15 Oct 2025 05:00:00 GMT</pubDate>
<description>Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomesMore than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities October 15, 2025, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co</description>
</item>
<item>
<title>argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025</title>
<link>https://6ix.com/company/argenx-se/news/argenx-announces-extraordinary-general-meeting-of-shareholders-on-november-18-2025</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/argenx-announces-extraordinary-general-meeting-of-shareholders-on-november-18-2025</guid>
<pubDate>Fri, 03 Oct 2025 20:01:00 GMT</pubDate>
<description>October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.The shareholders and all other persons with meeting rights are invited to</description>
</item>
<item>
<title>FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations</title>
<link>https://6ix.com/company/argenx-se/news/fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenx-se/news/fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations-1</guid>
<pubDate>Thu, 18 Sep 2025 13:00:00 GMT</pubDate>
<description>HOLLY SPRINGS, N.C., September 18, 2025--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx’ drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028.</description>
</item>
</channel>
</rss>